Extract the most out of precious neuroscience samples
Neurodegeneration, neuroinflammation, infectious disease, and neurotrauma can have devastating effects on the Central Nervous System (CNS) that impact cognitive function, behavior, mental health, and more. Understanding the role of CNS cells such as neurons, astrocytes, glia, and oligodendrocytes as well as the pathways involved in disorders such as Alzheimer’s, Parkinson’s, Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), and Multiple Sclerosis (MS) is crucial to disease prevention, detection, and treatment.
We know it’s difficult to acquire diseased and normal CNS tissue for research. When samples are available, extracting the most biological information from every experiment with a multi-omic platform that is easy to use is important. Traditional, low-plex methods of profiling RNA and protein such as PCR, western blotting, immunohistochemistry, or immunofluorescence staining provide limited information on CNS structure and functionality. RNA Sequencing, while more comprehensive for expression analysis, does not directly quantify transcripts, requires time-consuming, tedious steps and onerous data analysis and sacrifices the spatial arrangement of mRNAs within tissue.
NanoString offers two robust and widely-cited platforms for multiplexed proteomics and transcriptomics of challenging neuroscience sample types such as FFPE, cell lysates, and cerebrospinal fluid. The nCounter® Analysis System and GeoMx® Digital Spatial Profiler (DSP) can be used in tandem with minimal hands-on time for bulk and spatial profiling of RNA or protein to generate accurate, repeatable, and insightful results in less than 24 hours that get you to your next neuroscience publication faster.
Select from curated, multiplexed nCounter Gene Expression Panels and/or GeoMx DSP Protein assays and the Whole Transcriptome Atlas to build your own experiment. Take advantage of embedded CNS and immune cell typing signatures to quantify the relative abundance of 5 CNS cell types and 14 different immune cell types.
Profile 770 human or mouse genes involved in six fundamental themes of neurodegeneration. Includes CNS cell typing signatures.
Study neuroinflammatory disorders or CNS infections with assessment of 23 pathways across 770 human or mouse genes. Includes CNS and immune cell typing signatures.
Translate mouse models of Alzheimer’s disease to human studies with a panel that includes 30 clinically derived AD-associated modules discovered in the AMP-AD consortium study
Decipher the role of astrocytes, microglia, and oligodendrocytes in health and disease with a panel of 770 human or mouse genes. Includes CNS and immune cell typing signatures.
Profile 96+ human proteins associated with CNS cells, Alzheimer’s, and Parkinson’s from a single FFPE tissue section or fresh frozen tissue slice with spatial resolution. Customize your assay by adding protein targets of your choice.
Transcriptional profiling of paediatric ependymomas identifies prognostically significant groups.
The majority of supratentorial ependymomas in children contain oncogenic fusions, such as ZFTA-RELA or YAP1-MAMLD1. In contrast, posterior fossa (PF) ependymomas lack recurrent somatic mutations and are classified based on gene expression or methylation profiling into group A (PFA) and group B (PFB).
Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study.
The ability to investigate therapeutic interventions in animal models of neurodegenerative diseases depends on extensive characterization of the model(s) being used. There are numerous models that have been generated to study Alzheimer’s disease (AD) and the underlying pathogenesis of the disease.
Combination Treatment of CI-994 With Etoposide Potentiates Anticancer Effects Through a Topoisomerase II-Dependent Mechanism in Atypical Teratoid/Rhabdoid Tumor (AT/RT).
Purpose: Atypical teratoid/rhabdoid tumor (AT/RT) is arising typically in young children and is associated with a dismal prognosis which there is currently no curative chemotherapeutic regimen. Based on previous studies showing high histone deacetylase 1 (HDAC1) expression in AT/RT, the HDAC1 inhibitor CI-994 was used as a novel treatment strategy in this study.